Summit Therapeutics Inc

SMMT is in a Stage 2 Advancing (Corrective Reset) with higher lows/higher highs since mid-June. A Bullish Pivot Point has confirmed structural repair and shift toward upward mean-reversion. Price is tightly tracking rising 9EMA/20EMA, offering a favorable pullback entry into the EMA support zone. Medium-term bias remains bullish, supported by constructive volume and improving relative strength, while the primary risk is resistance at the 50-day SMA and potential distribution near overbought readings.

• ↑Phase III Harmony trial shows 34% reduction in death risk vs PD-1/chemo in NSCLC
• ↑Q4’25 cash of $713.4M with zero debt provides funding through key readouts
• ↓Weak profitability metrics highlight low returns amid high R&D spend